Unicef South Sudan Pharmaceutical Import Profile — Kenya (DGFT 2022–2026)

Name: Unicef South Sudan Pharmaceutical Import Records from India — 2 Products, $500.0K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Unicef South Sudan — Pharmaceutical Importer Profile (2026) | 2 Products, $500.0K Trade | TransData Nexus

Who Are the Verified Indian Suppliers to Unicef South Sudan?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Micro Labs Limited	$1.9M	74	33.7%
Medreich Limited	$832.9K	22	14.6%
Ipca Laboratories Limited	$444.7K	11	7.8%
Milan Laboratories (india) Private Limited	$426.5K	10	7.5%
Medopharm	$381.4K	15	6.7%
Milan Laboratories I Private Limited	$327.2K	17	5.7%
Mepro Pharmaceuticals Private Limited	$212.4K	9	3.7%
Sirmaxo Chemicals Private Limited	$200.0K	8	3.5%
Intas Pharmaceuticals Limited	$174.2K	7	3.1%
Panacea Biotec Limited	$150.0K	3	2.6%
Bharat Biotech International Limited	$146.4K	3	2.6%
Serum Institute Of India Private Limited	$137.3K	5	2.4%
Biological E Limited	$100.0K	2	1.8%
Biological E. Limited	$91.8K	2	1.6%
Strides Pharma Science Limited	$78.3K	11	1.4%
Macleods Pharmaceuticals Limited	$50.0K	2	0.9%
Acme Formulation Private Limited	$18.0K	1	0.3%
Cipla Limited	$8.3K	3	0.1%

Unicef South Sudan sources from 18 verified Indian suppliers across 115 distinct formulations. The supply base is diversified across 18 suppliers, reducing single-source dependency risk.

What Formulations Does Unicef South Sudan Import?

Formulation	Value	Ships
Amoxicillin dispersible tablets 250 MG	$379.2K	8
Amoxicillin dispersible tablets 250 MG	$346.8K	7
Povidone iodine 10% topical solution	$200.0K	4
Pharmaceutical goods/harmless medicinesmiloxy suspension Each 5ML reconstituedsuspension cont. amoxicillin	$180.7K	13
Amoxicillin 250 MG dispersible tablets	$150.0K	3
Amoxicillin 250MG dispersible tablets10x10s (194620 packs	$150.0K	3
Amoxicillin 250MG dispersible tablets 10x10s (128910 packs

What Products Does Unicef South Sudan Import?

Top Products by Import Value

1Artesunate$400.0K 2Quinine$100.0K

Unicef South Sudan Therapeutic Categories — 1 Specializations

Unicef South Sudan imports across 1 therapeutic categories, with Antimalarial & Antiparasitic (100.0%), representing the largest segments. The portfolio is concentrated — top 5 products = 100% of total imports.

Antimalarial & Antiparasitic

2 products · 100.0% · $500.0K

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Artesunate	Antimalarial & Antiparasitic	$400.0K	8	0.2%	14
2	Quinine	Antimalarial & Antiparasitic	$100.0K	2	0.5%	9

Key Metrics

Total Import Value$500.0K

Products2

Shipments10

Categories1

CountryKenya

#1 Rankings0

Indian Suppliers18

Formulations115

Top Categories

Antimalarial & Antiparasitic100.0%

Indian Suppliers

Last updated: March 28, 2026

Unicef South Sudan — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Unicef South Sudan is a humanitarian organization operating in South Sudan, focusing on providing essential services, including healthcare, to vulnerable populations. While its primary operations are based in South Sudan, the organization has established procurement activities in Kenya to facilitate the importation of pharmaceutical products. This strategic approach allows Unicef South Sudan to leverage Kenya's more developed infrastructure and regulatory environment for sourcing medical supplies. The organization collaborates with various suppliers to ensure the availability of essential medicines and medical equipment for its programs in South Sudan.

2Distribution Network

Unicef South Sudan's distribution network is designed to efficiently deliver medical supplies to its operations in South Sudan. By sourcing pharmaceutical products through Kenya, the organization benefits from Kenya's established logistics capabilities, including well-developed ports and transportation networks. This arrangement facilitates the timely and cost-effective movement of goods to South Sudan, ensuring that medical supplies reach their intended destinations without significant delays. The use of Kenya as a procurement hub also allows Unicef South Sudan to navigate the complex regulatory landscape of South Sudan more effectively.

Supplier Relationship Intelligence — Unicef South Sudan

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Unicef South Sudan's sourcing strategy exhibits a high degree of concentration, with a total import value of $500,000 USD from India across 10 shipments, primarily consisting of two products: Artesunate and Quinine. This focused approach suggests a strategic choice to procure specific, high-demand antimalarial medications essential for its programs. The consistent sourcing from Indian suppliers indicates a stable and reliable relationship, reducing the risks associated with supplier dependency. However, the limited product range may expose the organization to supply chain vulnerabilities if there are disruptions in the production or export of these specific medications.

2Supply Chain Resilience

The resilience of Unicef South Sudan's Indian supply chain is bolstered by its partnerships with multiple Indian pharmaceutical companies, including MICRO LABS LIMITED, MEDREICH LIMITED, and IPCA LABORATORIES LIMITED. This diversification across suppliers enhances the organization's ability to mitigate risks associated with single-source dependency. Additionally, the focus on finished pharmaceutical formulations, rather than raw APIs or bulk drugs, ensures that the products meet the necessary quality standards for direct use in medical treatments. While the reliance on international shipping routes introduces potential vulnerabilities, the established logistics capabilities of Kenya provide a buffer against such risks.

3Strategic Implications

Unicef South Sudan's concentrated sourcing pattern positions it to maintain strong, stable relationships with its Indian suppliers, ensuring a consistent supply of critical antimalarial medications. For Indian exporters, this presents an opportunity to strengthen partnerships with Unicef South Sudan by offering reliable and high-quality products tailored to the organization's specific needs. Expanding the product range to include other essential medicines could further enhance the organization's ability to meet the diverse healthcare needs of South Sudan's population.

TransData Nexus Research · Verified DGFT customs dataMar 2026

Importing Pharmaceuticals into Kenya — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Kenya

1Regulatory Authority & Framework

In Kenya, the Pharmacy and Poisons Board (PPB) serves as the primary regulatory authority overseeing the importation, distribution, and sale of pharmaceutical products. The PPB is responsible for ensuring that all medical products meet the required quality, safety, and efficacy standards before they enter the Kenyan market. Key legislation governing pharmaceutical imports includes the Pharmacy and Poisons Act, which outlines the procedures for product registration, importation, and distribution. For Indian generics to be marketed in Kenya, they must undergo a registration process with the PPB, which involves submitting product samples and documentation to verify compliance with Kenyan standards.

2Import Licensing & GMP

Importers of pharmaceutical products into Kenya are required to obtain an import license from the PPB for each consignment. This process involves submitting an import declaration form through the Kenya National TradeNet System (KESWS). Additionally, imported pharmaceutical products must meet Good Manufacturing Practice (GMP) standards recognized by the PPB. While the PPB does not specify particular GMP certifications, adherence to internationally recognized standards, such as WHO GMP, is generally accepted. Importers must ensure that their suppliers hold valid GMP certificates to facilitate the importation process.

3Quality & Labeling

Imported pharmaceutical products must undergo batch testing to confirm their quality and safety. Stability requirements are set to ensure that products maintain their efficacy throughout their shelf life. Labeling must be in English and include essential information such as the product name, active ingredients, dosage instructions, and expiry date. Serialization mandates may apply to enhance traceability and prevent counterfeit products from entering the market. Compliance with these requirements is essential for the legal sale and distribution of pharmaceutical products in Kenya.

4Recent Regulatory Changes

Between 2024 and 2026, Kenya's Ministry of Health, through the Pharmacy and Poisons Board (PPB), implemented stricter regulations on the importation and sale of pharmaceutical products. Notably, in January 2025, the PPB issued a directive prohibiting the importation, distribution, sale, or handling of unregistered pharmaceutical products, particularly those referencing the Indian Pharmacopoeia. This move aimed to address concerns over the influx of unregistered drugs into the Kenyan market and to ensure that all pharmaceutical products meet the PPB's registration requirements. (pulse.co.ke)

TransData Nexus Research · Kenya regulatory databasesMar 2026

Unicef South Sudan — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Unicef South Sudan's focus on importing antimalarial medications, specifically Artesunate and Quinine, aligns with the organization's mission to combat malaria, a prevalent and life-threatening disease in South Sudan. The high import value of Artesunate ($400,000) and Quinine ($100,000) underscores the critical demand for these treatments. The organization's strategic sourcing from India leverages the country's robust pharmaceutical manufacturing capabilities, ensuring access to quality medications at competitive prices. This approach enables Unicef South Sudan to provide effective malaria treatment options to the populations it serves.

2Sourcing Profile

Unicef South Sudan's sourcing strategy emphasizes the procurement of generic antimalarial medications from India, capitalizing on the country's extensive experience in producing high-quality generics. The focus on finished pharmaceutical formulations ensures that the products are ready for immediate use, streamlining the supply chain and reducing lead times. India's established reputation in the global pharmaceutical market makes it a reliable partner for Unicef South Sudan's procurement needs, aligning with the organization's objectives to provide essential healthcare services efficiently.

3Market Positioning

By importing and distributing essential antimalarial medications, Unicef South Sudan serves a critical segment of the South Sudanese healthcare market, focusing on the treatment and prevention of malaria. The organization's role is distinct from that of commercial entities, as it operates primarily through humanitarian aid and partnerships with international organizations to meet the healthcare needs of vulnerable populations. This positioning enables Unicef South Sudan to address specific health challenges in South Sudan, contributing to the overall improvement of public health in the region.

TransData Nexus Research · DGFT trade data analysisMar 2026

Seller's Guide — How to Become a Supplier to Unicef South Sudan

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to engage with Unicef South Sudan by offering high-quality antimalarial medications that meet the PPB's regulatory standards. Expanding the product range to include other essential medicines could further enhance the organization's ability to address the diverse healthcare needs of South Sudan's population. However, potential suppliers must navigate the regulatory landscape, ensuring compliance with Kenyan import regulations and the PPB's requirements to establish successful partnerships.

2Requirements & Qualifications

Indian exporters seeking to supply Unicef South Sudan and the Kenyan market must ensure that their pharmaceutical products are registered with the PPB and comply with Kenyan import regulations. This includes obtaining the necessary import licenses, adhering to GMP standards recognized by the PPB, and ensuring that labeling and packaging meet the PPB's requirements. Additionally, products must undergo batch testing and meet stability requirements to ensure quality and safety. Compliance with these standards is essential for successful market entry and distribution in Kenya.

3How to Approach

Indian exporters can approach Unicef South Sudan by establishing direct communication to understand the organization's specific procurement needs and product requirements. Participating in relevant tenders and responding to Requests for Proposals (RFPs) issued by Unicef South Sudan can provide opportunities for collaboration. Developing a comprehensive regulatory filing strategy that addresses the PPB's requirements, including product registration and import licensing, is crucial. Setting realistic timelines for product registration, importation, and distribution will facilitate smoother entry into the Kenyan market and alignment with Unicef South Sudan's procurement processes.

TransData Nexus Research · Industry procurement practicesMar 2026

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Buyer Matching: Unicef South Sudan identified across shipments using consignee name normalization.
2.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
3.Market Share: Calculated per product as Unicef South Sudan's capped value divided by total Indian exports for that product.
4.Shipment Count: Based on 10 individual customs records matching Unicef South Sudan.
5.Supplier Verification: Unicef South Sudan sources from 18 verified Indian suppliers across 115 formulations, confirmed from customs records.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

2 Products Tracked

1 therapeutic categories

Expert-Reviewed

By pharmaceutical trade specialists

Unicef South Sudan

Unicef South Sudan — Import Portfolio & Supplier Network